A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation

Active:	Yes
Cancer Type:	Multiple Myeloma Plasma cell neoplasm	NCT ID:	NCT06045806
Trial Phases:	Phase III	Protocol IDs:	CA089-1043 (primary) NCI-2024-01211 2022-501346-30 U1111-1280-9736
Eligibility:	18 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	Celgene
NCI Full Details:	http://clinicaltrials.gov/show/NCT06045806

Summary

The purpose of this study is to compare the efficacy, safety, and tolerability of ide-cel
with lenalidomide (LEN) maintenance to that of LEN maintenance alone in adult
participants with Newly Diagnosed Multiple Myeloma (NDMM) who have achieved a suboptimal
response post autologous stem cell transplantation (ASCT).

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.